Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol
Intervirology, ISSN: 0300-5526, Vol: 51, Issue: 6, Page: 407-409
2009
- 7Citations
- 6Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef6
- Captures6
- Readers6
- Mentions1
- News Mentions1
- News1
Most Recent News
Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV
STUDY INFORMATION OFFICIAL TITLE: Clinical Study of a Biological Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for the Treatment of Hepatitis C Infection CURRENT STATUS:
Article Description
Objective: We report elevated serum alanine aminotransferase (ALT) levels during pegylated interferon (PEG-IFN)-α-2a in a patient with chronic HCV without other clinical manifestations. Case Summary: A 38-year-old man presented for HCV infection evaluation. Serum aspartate aminotransferase (AST) and ALT levels were 43 and 116 U/l, respectively; RT-PCR blood analysis revealed HCV-RNA infection. PEG-IFN-α-2b plus ribavirin treatment induced both a rapid virologic response and a normalization of transaminase plasma levels. During follow-up, an increase in transaminase and HCV-RNA values prompted us to start a new antiviral treatment with PEG-IFN-α-2a plus ribavirin. Four months later, after the follow-up, a new blood test documented both a HCV-RNA titer <50 U/ml and an increase in ALT and AST plasma levels. Immunostaining of the liver biopsy showed an accumulation of PEG-IFN-α-2a. PEG-IFN-α-2a elimination and the addition of recombinant IFN-α-2a induced normalization of the plasma transaminase levels in about 2 months. Conclusion: We postulate PEG-IFN-α-2a treatment because both the molecular weight and the distribution volume of the PEG-IFN may accumulate in the liver resulting in an increase of plasma transaminase levels. In contrast, during PEG-IFN-α-2b treatment, we did not document any increase in plasma transaminase values probably because of the lower molecular weight of the PEG. Copyright © 2009 S. Karger AG, Basel.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=61349198232&origin=inward; http://dx.doi.org/10.1159/000205266; http://www.ncbi.nlm.nih.gov/pubmed/19258719; https://karger.com/INT/article/doi/10.1159/000205266; http://www.karger.com/?doi=10.1159/000205266; http://www.karger.com/Article/Abstract/205266
S. Karger AG
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know